Related Experiment Videos
Development of argatroban as an anticoagulant and antithrombin agent in Japan
1Development Coordination Department, Research and Development Division, Mitsubishi Pharma Corporation, Tokyo, Japan. Hidenobu@mh.m-pharma.co.jp
Insights
Argatroban, a direct thrombin inhibitor, effectively treats chronic arterial occlusion, acute cerebral thrombosis, and improves hemodialysis in AT-deficient patients. It demonstrates benefits by improving symptoms and enabling procedures previously hindered by clotting.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Argatroban is a synthetic direct thrombin inhibitor.
- It has established uses in Japan for specific thrombotic conditions.
- Its efficacy is linked to antithrombotic mechanisms.
Purpose of the Study:
- To evaluate the therapeutic applications of argatroban in distinct clinical scenarios.
- To assess argatroban's impact on chronic arterial occlusion, acute cerebral thrombosis, and hemodialysis.
- To understand argatroban's role in managing patients with antithrombin (AT) deficiency or reduced AT levels.
Main Methods:
- Clinical observation and assessment of treatment outcomes in patients with chronic arterial occlusion.
- Comparative analysis of argatroban versus placebo in acute cerebral thrombosis, monitoring neurological symptoms and coagulation parameters.
- Evaluation of argatroban as a heparin alternative in hemodialysis for patients with clotting issues.
Main Results:
- In chronic arterial occlusion, argatroban improved skin temperature, reduced ulcer size, and decreased thrombin-antithrombin complex levels.
- Significant improvement in neuronal symptoms was observed in acute cerebral thrombosis patients treated with argatroban compared to placebo.
- Activated partial thromboplastin time (aPTT) increased approximately 1.5-fold, and fibrinopeptide A was reduced in the acute cerebral thrombosis group.
- Argatroban facilitated hemodialysis in patients experiencing dialyzer clotting, serving as a viable alternative to heparin.
Conclusions:
- Argatroban demonstrates significant therapeutic value across multiple indications, including vascular occlusion and thrombosis.
- Its use improves clinical outcomes and procedural success in specific patient populations.
- Argatroban offers a critical alternative to heparin in hemodialysis for patients prone to clotting.
Abstract:
Argatroban is a synthetic direct thrombin inhibitor which has been used in Japan for three indications, namely, chronic arterial occlusion, acute cerebral thrombosis and hemodialysis in AT-deficient patients or in patients with decreased AT. In patients with chronic arterial occlusion, argatroban increased the skin temperature, reduced the size of skin ulcers, and decreased the thrombin-antithrombin complex. In patients with acute cerebral thrombosis, neuronal symptoms improved significantly compared with the placebo group, wherein activated partial thromboplastin time (aPTT) was prolonged by about 1.5-fold and fibrinopeptide A was reduced. In some patients in whom hemodialysis is difficult due to the generation of blood clots in the dialyzer, hemodialysis is now possible with the replacement of heparin by argatroban.